Q3 2023 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2023-11-13 · accession 0000904454-23-000604
$200.8M
Reported value
30
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $18.9M | 9.41% | 331,416 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $18.1M | 9.02% | 1,489,025 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $17.6M | 8.78% | 145,357 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $16.9M | 8.39% | 349,300 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $15.8M | 7.89% | 458,659 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $15.3M | 7.64% | 163,772 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $12.9M | 6.41% | 556,928 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $12.7M | 6.33% | 431,693 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $12.3M | 6.12% | 563,345 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $11.8M | 5.89% | 427,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $11.6M | 5.78% | 556,553 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $9.9M | 4.94% | 504,700 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $8.0M | 3.99% | 895,821 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $7.5M | 3.71% | 325,356 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $7.3M | 3.65% | 870,870 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $2.4M | 1.21% | 961,251 | Common | SOLE |
| 320703101 | — | CALIDI BIOTHERAPEUTICS INC | $415,625 | 0.21% | 125,000 | Common | SOLE |
| G33032122 | — | ARES ACQUISITION CORP | $333,611 | 0.17% | 504,706 | Common | SOLE |
| G1355U121 | — | BRIDGETOWN HOLDINGS LTD | $304,300 | 0.15% | 895,000 | Common | SOLE |
| 17144M110 | — | CHURCHILL CAPITAL CORP VII | $168,784 | 0.08% | 548,000 | Common | SOLE |
| 320703119 | CLDWW | CALIDI BIOTHERAPEUTICS INC | $144,144 | 0.07% | 655,200 | Common | SOLE |
| G2476C123 | CDAWF | COMPASS DIGITAL ACQUISITION CORP | $101,271 | 0.05% | 459,906 | Common | SOLE |
| 17143W119 | — | CHURCHILL CAPITAL CORP VI | $86,400 | 0.04% | 540,000 | Common | SOLE |
| G7641C114 | — | ROSS ACQUISITION CORP II | $49,023 | 0.02% | 439,666 | Common | SOLE |
| 20607U116 | CNDAW | CONCORD ACQUISITION CORP II | $42,589 | 0.02% | 408,333 | Common | SOLE |
| G63836111 | IVCPW | SWIFTMERGE ACQUISITION CORP | $34,594 | 0.02% | 490,000 | Common | SOLE |
| G9845F117 | LSBWF | YS BIOPHARMA CO LTD | $17,150 | 0.01% | 489,999 | Common | SOLE |
| 56608A113 | — | MARBLEGATE ACQUISITION CORP | $13,524 | 0.01% | 735,000 | Common | SOLE |
| 43734R111 | — | HOME PLATE ACQUISITION CORP | $0 | — | 690,000 | Common | SOLE |
| 17144T115 | — | CHURCHILL CAPITAL CORP V | $0 | — | 612,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.